Jakavi 20mg Tablet contains Ruxolitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor used primarily in the treatment of myeloproliferative disorders. It is indicated for patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis, to reduce splenomegaly and alleviate disease-related symptoms. Jakavi is also approved for the treatment of polycythemia vera in patients who are resistant or intolerant to hydroxyurea. The mechanism of action involves the inhibition of aberrant JAK-STAT signaling pathways, which are implicated in the pathogenesis of these hematologic conditions, thereby reducing pathological cell proliferation and inflammation. Jakavi 20mg Tablet is administered orally, with dosage individualized based on patient response and tolerability. Common adverse effects include anemia, thrombocytopenia, bruising, dizziness, and headache; therefore, regular monitoring of blood counts is essential during therapy. Caution is advised in patients with hepatic or renal impairment. Jakavi should be prescribed and managed by healthcare professionals experienced in the treatment of myeloproliferative neoplasms to ensure optimal therapeutic outcomes and minimize potential risks.